Glaukos Corp (GKOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Glaukos Corp (GKOS) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.09 Million) by net assets ($769.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Glaukos Corp - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Glaukos Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Glaukos Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
Glaukos Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glaukos Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QUBE Holdings Ltd
AU:QUB
|
0.081x |
|
Tianshui Huatian Technology Co Ltd
SHE:002185
|
0.051x |
|
Elis SA
PA:ELIS
|
0.154x |
|
SDIC Essence Holdings Co Ltd
SHG:600061
|
0.162x |
|
Rayonier Inc
NYSE:RYN
|
0.116x |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
-0.051x |
|
ISS A/S
CO:ISS
|
0.007x |
|
Pegasystems Inc
NASDAQ:PEGA
|
0.201x |
Annual Cash Flow Conversion Efficiency for Glaukos Corp (2012–2024)
The table below shows the annual cash flow conversion efficiency of Glaukos Corp from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see GKOS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $766.93 Million | $-61.32 Million | -0.080x | +36.08% |
| 2023-12-31 | $461.77 Million | $-57.76 Million | -0.125x | -100.39% |
| 2022-12-31 | $530.00 Million | $-33.08 Million | -0.062x | -248.33% |
| 2021-12-31 | $587.15 Million | $24.71 Million | 0.042x | +222.18% |
| 2020-12-31 | $667.45 Million | $-22.99 Million | -0.034x | -6184.16% |
| 2019-12-31 | $673.27 Million | $-369.00K | -0.001x | -100.51% |
| 2018-12-31 | $173.86 Million | $18.86 Million | 0.109x | -41.21% |
| 2017-12-31 | $138.20 Million | $25.51 Million | 0.185x | +75.85% |
| 2016-12-31 | $117.27 Million | $12.31 Million | 0.105x | +556.64% |
| 2015-12-31 | $95.19 Million | $-2.19 Million | -0.023x | -152.04% |
| 2014-12-31 | $-160.90 Million | $-7.11 Million | 0.044x | -50.52% |
| 2013-12-31 | $-149.04 Million | $-13.30 Million | 0.089x | -96.09% |
| 2012-12-31 | $-8.95 Million | $-20.45 Million | 2.285x | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more